Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531067 | 1.00 | LPL (0.39) | LPLLIPGF11CYP4F2CYP4A11 | |
| SCHEMBL7249357 | 0.85 | LIPG (0.42) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL2699203 | 0.84 | LIPG (0.39) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL19336172 | 0.83 | LIPG (0.51) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL14696743 | 0.82 | LPL (0.40) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL17261770 | 0.81 | LPL (0.37) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL2522663 | 0.81 | LPL (0.37) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL258023 | 0.81 | LPL (0.39) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL2522891 | 0.79 | LPL (0.36) | LPLLIPGF11UCHL1JAK2 | |
| SCHEMBL14694384 | 0.78 | LPL (0.37) | LPLLIPGF11UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4013499-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114621204-A | Pyrimidinedione-containing acyl polysubstituted piperazine derivative and preparation method and application thereof | 山东大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-114222730-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20210053967-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021030438-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030438-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | ITGB7, ITGB4, ITGA4 | LPL 2582/4885LIPG 1133/4885F11 165/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | LPL 3834/4885LIPG 3564/4885F11 1213/4885 |
| US-20210053967-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | LPL 3161/4885LIPG 1634/4885F11 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.